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P
araneoplastic disorders can be broadly de¢ned as those
that are caused by a remote e¡ect of a cancer, not by
direct tumor in¢ltration or tissue damage caused by
metastases.These remote e¡ects can be due to secretion
of biologically active peptides or, in some cases, by im-
munologic e¡ects of the tumor on the resident immune system.
Paraneoplastic pemphigus (PNP) is an example of a paraneoplas-
tic phenomenon caused by an autoimmune disease initiated by an
underlying lymphoproliferative disorder (Anhalt et al, 1990). Its
clinical presentation can be quite variable, which is why it re-
mained unrecognized for so long (Redon et al, 1983; Matsuoka
et al, 1989; Panielieyva, 1990). PNP can be de¢ned and identi¢ed
by the following features: (1) painful stomatitis and a polymor-
phous cutaneous eruption with lesions that may be blistering or
lichenoid or may resemble erythema multiforme or a drug erup-
tion; (2) histologic ¢ndings that re£ect the variability of the cuta-
neous lesions, showing acantholysis, lichenoid, or interface
change; (3) direct immuno£uorescence demonstrating deposition
of IgG and complement in the epidermal intercellular spaces, and
often granular/linear complement deposition along the epidermal
basement membrane zone; (4) serum autoantibodies that bind the
cell surface of skin and mucosae in a pattern typical for pemphi-
gus, but in addition bind to simple, columnar, and transitional
epithelia; (5) the serum autoantibodies identify desmogleins 1
and 3, as well as members of the plakin family of epithelial pro-
teins, including desmoplakins I and II, envoplakin, periplakin,
bullous pemphigoid antigen 1 (BPAg1), and plectin. The inci-
dence of the disease is unknown, but it is less common than
pemphigus vulgaris (PV) or foliaceus (PF). Clinical features of
the disease can mimic those seen in a drug reaction, erythema
multiforme, Stevens-Johnson syndrome, or toxic epidermal ne-
crolysis. Moreover, there is some evidence that the majority of
cases are still not properly diagnosed.
PNP is associated in the majority of cases with non-Hodgkin’s
lymphoma, chronic lymphocytic leukemia, and Castleman’s dis-
ease. Treatment of the autoimmune disease is di⁄cult, and most
patients die from complications, including pulmonary involve-
ment with respiratory failure.
CLINICAL FEATURES
Over the years, we have found that the most constant clinical
feature of PNP is the development of painful and persistent
stomatitis (Fig 1). In some patients only the oropharynx is a¡ected,
and skin lesions are never observed (Bialy Golan et al, 1996). Sto-
matitis is the earliest presenting sign and, despite treatment, is the
one feature that persists throughout the course of disease, being
extremely resistant to therapy. Stomatitis presents with erosions
and ulcerations that can a¡ect all surfaces of the oropharynx. The
lesions are clinically distinctive. Because of the presence of
epithelial necrosis and lichenoid changes, the lesions are much
more necrotic and do not show the ragged super¢cial erosions
characteristic of PV. They also preferentially localize to the lateral
borders of the tongue and characteristically extend onto and in-
volve the vermilion of the lips. This involvement of the tongue
appears to be the reason for the extreme oral pain reported by
a¡ected patients. The cutaneous lesions of PNP are much more
variable than those seen in PV or PF, and di¡erent morphologies
may be observed in an individual patient at di¡erent times. In
some cases, there may be episodes of waves of blistering a¡ecting
the upper trunk, head and neck, and proximal extremities. These
blisters rupture easily, leaving erosions. The blisters on the extre-
mities can be quite tense, resembling those seen in bullous pem-
phigoid, or they can have surrounding erythema, thus clinically
resembling erythema multiforme. On the upper chest and back,
con£uent erosive lesions can develop, producing a picture resem-
bling toxic epidermal necrolysis (TEN).The similarity of the mu-
cocutaneous features to erythema multiforme/TEN explains why
this is the most common di¡erential diagnosis for PNP. However,
erythema multiforme and TEN are self-limited events that evolve
and resolve over several weeks, whereas PNP is a relentlessly pro-
gressive disease that continuously evolves over months.
In PVand PF, the tissue injury is mediated exclusively by auto-
antibody, and the blistering acantholytic lesions are evident. In
PNP, there is substantial evidence that the autoantibodies alone
do not cause all of the tissue injuryhence the variable clinical
and histologic presentation. There is cell-mediated cytotoxicity,
which can cause the clinical and histologic ¢ndings of lichenoid
change, individual cell necrosis or con£uent cell necrosis that
causes lichenoid lesions, or lesions that resemble erythema multi-
forme or TEN (Nguyen et al, 2001). Cutaneous lichenoid lesions
may be the only cutaneous signs of the disease, or they may de-
velop in lesions that had previously been blistered, which is a dis-
tinctive ¢nding in PNP (Stevens et al, 1993). These lesions consist
of in¢ltrated erythematous papules and plaques, and are always
accompanied by stomatitis. In the chronic form of the disease
and after treatment, this lichenoid eruption may predominate
over blistering on the cutaneous surface. Both blisters and liche-
noid lesions a¡ecting the palms and the soles, as well as the par-
onychial tissues, are common; they help to distinguish PNP from
PV, in which acral and paronychial lesions are uncommon. PNP
has also been identi¢ed in a horse (Williams et al, 1995) and a dog
(de Bruin et al, 1999). In animal species, it has the same associated
neoplasms and clinical outcomes.
PNP is the only form of pemphigus that has involvement of tis-
sues not covered by strati¢ed squamous epithelium. Approximately
30%^40% of cases will develop pulmonary injury, often with a
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fatal outcome (Fullerton et al, 1992). The earliest symptoms are
progressive dyspnea associated initially with an absence of
¢ndings on chest radiography. Pulmonary functions studies show
air£ow obstruction, involving large and small airways. In£amma-
tion of the large airways evolves, and endoscopic biopsy can show
acantholysis of bronchial respiratory epithelium. Pulmonary
function deteriorates in most cases despite immunosuppressive
therapy, and radilologic, histologic, and functional changes char-
acteristic of bronchiolitis obliterans develop (Nousari et al, 1999a).
PATHOGENESIS
PNP is associated with a limited number of lymphoproliferative
neoplasms. There have been fewer than a handful of cases in
which an underlying neoplasm could not be identi¢ed. The
approximate frequency of speci¢c neoplasms is as follows:
(1) Non-Hodgkin’s lymphoma (NHL), 42%; (2) chronic lympho-
cytic leukemia (CLL), 29%; (3) Castleman’s disease (giant follicu-
lar hyperplasia), 10%; (4) thymoma (malignant and benign), 6%;
(5) sarcoma, 6%; (6) Waldenstrom’s macroglobulinemia, 6% (Fig
2). The majority of cases are associated with NHL and CLL, but
an unusual ¢nding is the disproportionate frequency of Castle-
man’s disease. This is a very rare lymphoproliferative disorder,
and so this association must give us some clue as to the etiology
of the autoimmunity. The association with Castleman’s is even
more striking in pediatric cases, where it is the underlying neo-
plasm in almost all patients (Mimouni et al, 2002). Prior to the
description of PNP, there were many cases of Castleman’s disease
associated with atypical forms of pemphigus, and we suspect
most were cases of PNP (Tagami et al, 1978; Plewig et al, 1990).
More common cancers, such as adenocarcinomas of breast,
bowel, and lung or basal cell and squamous cell carcinoma of skin
have not been associated with PNP.There are a very few reports of
PNP occurring with tumors, such as squamous cell carcinoma.
Most of these diagnoses have not been con¢rmed by immuno-
chemical testing, however, so the association remains unproven.
At present, we can only speculate about the potential mechan-
isms by which these tumors induce autoimmunity against
epithelial proteins. Initially, we thought that the tumors might
constitutively or anomalously express epithelial proteins. This
phenomenon does occur in several neurologic paraneoplastic syn-
dromes where the tumor expresses a normal host protein.When
presented by the tumor cells, however, these proteins are targeted
by the antitumor immune response and cross-react with normal
constitutive proteins (Kornguth, 1989). In PNP, however, we have
no evidence that the tumors themselves anomalously express
epithelial proteins.We also have no evidence that the tumor cells
produce the pathogenic autoantibody. For example, in cases of
Waldenstrom’s the autoantibody produced is polyclonal, IgG
class, so it could not be produced by the myeloma and is a pro-
duct of the host immune response.
There is at least one attractive alternative hypothesis, given the
evidence that dysregulated cytokine production by tumor cells
may drive the development of autoimmunity. For example, it
has been observed that treatment with cytokines may induce
PNP (Kirsner et al, 1995), raising the possibility of more complex
interactions between the tumor cells and the immune system.
Interleukin 6 (IL-6) has received some attention, as patients with
PNP show markedly elevated serum levels of this cytokine (Fig 3)
(Nousari et al, 1999b). It has been observed that the tumor cells iso-
lated from some cases of Castleman’s disease, non-Hodgkin’s lym-
phoma, and CLL (Yee et al, 1989) secrete large amounts of IL-6
in vitro. It is tempting to think that this might be the link to the
frequent association of Castleman’s with PNP. IL-6 promotes B
cell di¡erentiation and drives immunoglobulin production, and
dysregulated IL-6 production has been implicated in speci¢c auto-
immune diseases. Castleman’s tumors are known to be associated
with other autoimmune phenomena such as myasthenia gravis
and autoimmune cytopenias, and Castleman’s patients have also
been shown to have high serum levels of IL-6. Symptoms attribu-
table to Castleman’s tumors can be abolished by complete excision
of the a¡ected node(s) and, coincidentally, serum IL-6 levels revert
to normal. Perhaps the most compelling evidence arises from
the observation that administration of anti-IL-6 monoclonal
Figure1. Stomatitis, typical of that seen in essentially all cases of
paraneoplastic pemphigus. This man has associated Castleman’s disease.
The erosions involve the entire vermillion of the lips, and the tongue and
buccal mucosal surfaces are di¡usely eroded and extremely painful. This
presentation is so uniform that absence of this clincial sign should cast
doubt on the diagnosis.
Figure 2. The proportion of speci¢c neoplasms associated with
paraneoplastic pemphigus is shown graphically. The exact percen-
tages vary as additional cases accrue, but the three most commonly asso-
ciated neoplasms have always been non-Hodgkin’s lymphoma, chronic
lymphocytic leukemia, and Castleman’s disease. The sarcomas associated
with this are unusual retroperitoneal sarcomas that appear to be of lymph
node origin (such as dendritic follicular cell sarcomas). Other refers to cases
of retroperitoneal tumors with such primitive di¡erentiation that speci¢c
classi¢cation cannot be made.
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antibodies can e¡ectively reverse systemic manifestations of Cas-
tleman’s disease. This was shown in a case of autoimmune throm-
bocytopenia associated with Castleman’s. Administration of anti-
IL-6 caused a prompt elevation of platelet counts and elimination
of the patient’s ‘‘B’’ symptoms (Beck et al, 1994). These observations
are intriguing, but further study of cytokine regulation in these
complex and very ill patients is challenging.
The immunopathology of PNP is more complex than that of
PV and PF, where the tissue injury is secondary to autoantibody
binding to epidermal cells alone. There is evidence of cell-
mediated cytotoxicity, which could explain the histologic and
clinical features of lichenoid change and individual cell necrosis.
Almost all patients have autoantibodies against desmogleins, de-
monstrable by ELISA, and we know that these antibodies are
pathogenic. If the desmoglein autoantibodies from these patients
are injected into neonatal mice, acantholytic skin lesions are in-
duced (Amagai et al, 1998; Reich et al, 1999). However, no other
internal organs are involved and there is no lymphocyte-medi-
ated cell damage. None of features of the disease that suggest cell-
mediated autoimmunity, then, are recreated by immunoglobulin
injections alone. This is also an indication that humoral immunity
by itself will reproduce features of acantholysis, but reproduction
of the cell-mediated immune attack may be necessary to reproduce
all of the features of the disease in an animal model.
LABORATORY FINDINGS
PNP is clinically complex, and so far we have found that the
most reliable serologic markers for it are identi¢cation of polyclo-
nal IgG autoantibodies against plakin proteins and, in most cases,
desmogleins 1 and 3. The plakins are a group of sequence-related
proteins found in the intracellular plaque of desmosomes and
hemidesmosomes; they mediate attachment of cytoskeletal inter-
mediate ¢laments to transmembrane adhesion molecules such as
the desmogleins. Autoantibodies against these proteins are the
most reliable markers for the disease. The most characteristic and
consistently recognized plakin antigens are envoplakin (Kim et al,
1997) and periplakin (Mahoney et al, 1998) (210 and 190 kDa,
respectively). The next most frequently detected are antibodies
against desmoplakins I and II (250 and 210 kDa, respectively). Less
commonly, patients recognize bullous pemphigoid Ag 1 (230
kDa), plectin, and plakoglobin. The identity and frequency of an
antigen band at 170 kDa is not well de¢ned. PNP patients may also
have clinical and serologic evidence of other autoimmune phe-
nomena such as myasthenia gravis and autoimmune cytopenias.
To screen for PNP autoantibodies, we can test for IgG autoan-
tibodies by indirect immuno£uorescence (IF) reactive with ro-
dent urinary bladder epithelium. A positive result implies the
presence of plakin autoantibodies; however, the sensitivity and
speci¢city of this serologic test are only about 75% and 83%,
respectively (Helou et al, 1995). More speci¢c and sensitive tests
include immunoblotting against epidermal cell extracts, which
can e¡ectively detect antibodies against envoplakin, periplakin,
and desomplakin, and immunoprecipitation using radiolabeled
keratinocyte extracts, which can detect antibodies against any of
the plakin proteins.
This autoantibody pro¢le is more complex than that observed
in PV or PF, where autoantibodies are produced only against the
desmogleins. The humoral immunity in PNP may represent an
example of eipitope spreading in which patients develop autoan-
tibodies against structurally related plakin proteins and struc-
turally unrelated transmembrane cell surface proteins (the
desmogleins) that are physically linked to the plakin proteins in
the desmosome and hemidesmosome (Bowen et al, 2000).
PATHOLOGY
The clinical features of paraneoplastic pemphigus are variable,
and this is re£ected by potential variability in the histopathology
of lesions (Horn and Anhalt, 1991; Mehregan et al, 1993). The sto-
matitis is extremely severe, and many biopsies from ulcerative le-
sions yield nonspeci¢c changes of in£ammation and ulceration. If
we can biopsy perilesional epithelium, suprabasilar acantholysis
of the oral mucosa may be observed.
Similarly, if we biopsy intact cutaneous blisters, suprabasilar
acantholysis is present. Unlike other forms of pemphigus, in PNP
there may be substantial in£ammatory cell in¢ltration of early
lesions. Nonblistering lesions can show individual keratinocyte ne-
crosis with lymphocytic in¢ltration into the epidermis, reminis-
cent of that seen in erythema multiforme or graph versus host
disease. In addition, vacuolar interface change with sparse lympho-
cytic in¢ltrate of the basilar epithelium can be seen in some areas;
they resemble cutaneous lupus erythematosus. The lichenoid skin
lesions show areas of dense lymphocytic in¢ltrate in the upper
Figure 3. Patients with paraneoplastic
pemphigus and appropriate controls
were studied for elevated serum IL-6
levels. A subset of patients with severe, ra-
pidly progressive autoimmunity showed
marked elevations of IL-6, and the overall
average level was signi¢cantly above control
patient values. Patients with PV or PF asso-
ciated with neoplasms such as adenocarcino-
mas, basal or squamous cell carcinomas, and
so forth, did not show any similar elevations.
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dermis and individual lymphocytes in¢ltrating into the epithelium
with occasional individual cell necrosis. The histopathologic varia-
bility of this disease may be related to the fact that it is a presumed
antitumor immune response (see below). If this speculation is cor-
rect, we would expect to observe a combination of both humoral
and cell-mediated immunity that is aberrantly directed against nor-
mal epithelium. In such a setting, we would expect to see changes
of the sort described above. This degree of cell- mediated immu-
nity is not seen in PV or PFhence the unique histopathologic
features and, presumably, the unique clinical features as well.
Patients should have evidence of IgG autoantibodies bound to
the cell surface of a¡ected epithelium by direct immuno£uores-
cence. False negatives are more common in PNP than in PV,
however, and repeated biopsies may be necessary to demonstrate
this ¢nding. In a minority of cases, we might also see a combina-
tion of both cell surface and basement membrane zone deposition
of IgG and complement components, but the absence of this
combined cell surface/basement membrane zone staining does
not negate the diagnsois.
DIAGNOSIS
Not all patients demonstrate all of the ¢ve criteria that were ori-
ginally proposed to de¢ne the disease.We propose that the fol-
lowing represent the minimal criteria for diagnosis of PNP with
a high degree of con¢dence.
1 Painful, progressive stomatitis, with preferential involvement
of the tongue. This ¢nding is so consistent that it is unreason-
able to consider the diagnosis in its absence.
2 Histologic features of acantholysis or lichenoid or interface
dermatitis. Although acantholysis is most readily detected in
oral lesions, the necrosis and secondary in£ammation make
this di⁄cult to detect without repeated biopsies. Some patients
never develop skin lesions; some show only lesions that clini-
cally and histologically are lichenoid or resemble erythema
multiforme. Direct IF is very frequently negative, and the
serologic markers for the disease are so speci¢c that demons-
tration of tissue-bound autoantibodies is not an essential
criterion.
3 Demonstration of antiplakin autoantibodies. These are the key
serologic markers for the entity. Positive indirect IF on rodent
bladder is readily available but not highly reliable. Immuno-
chemical techniques are much more precise and should de-
monstrate, at a minimum, autoantibodies against periplakin
and/or envoplakin (Kiyokawa et al, 1998). Patients with PNP
should have a positive indirect IF test on monkey esophagus
and have antibodies against desmoglein 3 by ELISA. This will
not discriminate between PV and PF, however.
4 Demonstration of an underlying lymphoproliferative neo-
plasm. Approximately two-thirds of cases arise in the context
of known malignant disease, most often NHL or CLL. In ap-
proximately one-third of cases, there is no known neoplastic
lesion at the time the mucocutaneous disease develops. These
cases tend to be associated with Castleman’s disease, abdominal
lymphoma, thymoma, or retroperitoneal sarcomas. In most
cases, the occult neoplastic lesion can be detected by computer-
ized tomography scan of the chest, abdomen, and pelvis.
The major di¡erential diagnosis for patients with just oral in-
volvement should include PV, oral lichen planus, and major
aphthous stomatitis. More lichenoid skin lesions and mucositis
can closely resemble extensive lichen planus. Patients with skin
and oral involvement most closely resemble erythema multi-
forme, TEN, or PV. A small number of patients with recurrent
erythema multiforme major have antibodies against desmopla-
kins and will therefore have a positive indirect IF on bladder
epithelium. These cases are distinguished from PNP in several
ways: (1) they do not have an underlying malignancy; (2) they
do not have antibodies against the plakin proteins that are more
speci¢c for PNP, that is, envoplakin and periplakin; and (3) the
antibodies are transient and are only detecable during episodes
of active disease (Foedinger et al, 1995). The autoantibodies in
PNP are constantly present.
A small number of patients appear to have PNP, but do not
have demonstrable circulating autoantibodies. These patients tend
to have predominantly lichenoid skin and mucosal lesions, but
they behave in most other ways like antibody-positive patients
and have the same underlying neoplasms. Because the de¢nition
of the disease relies so heavily on demonstration of the speci¢c
autoantibody markers, further study is required to know how to
classify these patients
TREATMENTAND PROGNOSIS
The prognosis for PNP depends on the nature of the underlying
malignancy. Although the disease is initiated by the tumor, sim-
ply debulking the tumor or reducing tumor burden through che-
motherapy will not halt disease progression. It seems that once
the autoimmune disease is initiated, it progresses independently
of the underlying neoplasm. An example of the disconnect be-
tween tumor burden and autoimmunity is found in a case re-
ported by Fullerton and colleagues (Fullerton et al, 1992) in
which PNP developed after successful autologous bone marrow
transplantation for non-Hodgkin’s lymphoma. This patient was
free of detectable tumor burden at the time of his death, but he
died of pulmonary injury secondary to PNP. The patient did
receive an autologous bone marrow transplant and therefore
received his own memory T cells, which may have induced the
disease even after successful treatment of the malignancy. It is also
possible that individual malignant lymphoid cells that were not
detectable by routine autopsy methods persisted after the trans-
plant and were adequate to induce the PNP. In any case, this
would indicate that autologous bone marrow transplantation is
probably not a potential treatment for the autoimmune disease.
To date, there have been no reports of patients receiving an allo-
genic bone marrow transplant in the setting of PNP, so it is not
known what e¡ect that treatment might have.
There does seem to be more hope if the patient has an asso-
ciated benign or localized tumor. For example, if a patient has
an encapsulated Castleman’s tumor or a benign thymoma that
has been entirely surgically excised, the disease can improve sub-
stantially or enter a complete remission (Plewig and Jansen, 1991).
This remission may take one to two years after surgery, however,
so continued immunosuppression is required, and many patients
succumb to complications in this prolonged postoperative period.
A suggested regimen involves combined use of prednisone, 0.5
mg/kg; cyclopsporine, 5 mg/kg; and oral cyclophosphamide, 2
mg/kg. These medications should be tapered as symptoms im-
prove. In pediatric cases with respiratory disease, the persistent
autoimmunity immediately post-surgery can cause ongoing pul-
monary injury, and lung transplantation might be required for
long-term survival (Chin et al, 2001).
On the other hand, there is no evidence that any individual
therapeutic regimen is consistently e¡ective in patients with ma-
lignant neoplasms. For unknown reasons, cases associated with
NHL seems to be more di⁄cult to treat than those associated
with CLL. Although there are a couple of individual reports of
long-term survivors (Camisa et al, 1992), almost all patients with
NHL or CLL will succumb within three months to two years
after diagnosis. Oral corticosteroids in a dose of 0.5^1mg/kg will
produce partial improvement but not complete resolution of le-
sions. Cutaneous lesions respond more quickly to therapy,
whereas the stomatitis is generally more refractory; the pulmon-
ary disease seems to progress even if the mucositis improves.
Aside from corticosteroids, many other agents have been tried in
individual cases on an anecdotal basis, but none have proved to be
particularly e¡ective. Methods that have been tried and have of-
ten failed include immunosuppression with cyclophosphamide or
azathioprine, gold, dapsone, plasmapheresis, photopheresis, and
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high-dose intravenous immunoglobulins. A subset of patients,
usually with CLL as an underlying neoplasm, responded to a
combination of prednisone, 0.5^1 mg/kg/day, and cyclosporine,
5 mg/kg/day (Sthle-Backdhl et al, 1995). Additional treatment
with intermittent pulse cyclophosphamide to control the under-
lying CLLwas usually also used in these cases and may have con-
tributed to the good outcome. Some patients show improvement
after treatment with rituximab in combination with prednisone
and cyclophosphamide (Borradori et al, 2001). It is not known
why this autoimmune disease is so refractory to the kind of im-
munosuppressive treatments that usually work well in PV or
other autoimmune diseases.
The exact cause of death in PNP has been attributed to multi-
ple factors including sepsis, gastrointestinal bleeding, ‘‘multiorgan
failure,’’and respiratory failure. Patients with B cell neoplasms are
known to have a high frequency of autoimmune cytopenias, and
they may develop more than one neoplasm-associated autoim-
mune disease. In some cases of PNP, fatal episodes of sepsis are
suspected to have occurred because of sudden and unexplained
neutropenia, possibly due to this mechanism.
Respiratory failure is increasingly recognized as a common
terminal event. It had been unrecognized earlier because in the
earliest phase of the disease the patient complains of shortness of
breath with no remarkable imaging changes and with an obstruc-
tive pattern on pulmonary function tests that is often attributed
to a history of smoking, asthma, and the like. Despite its benign-
appearing onset, however, the development of shortness of breath
with obstructive disease, progressing to bronchiolitis obliterans, is
a terminal pathway in most cases. The exact mechanisms by
which this pulmonary disease occurs are not clear.We do know
that these patients have autoantibodies that react with desmopla-
kins and that desmoplakins are present in respiratory epithelium.
It is thus possible that respiratory failure may be due to autoanti-
body-mediated injury to bronchial epithelium, with plugging of
terminal alveoli with air£ow obstruction and ventilation profu-
sion abnormalities. Additionally, direct damage to alveolar
epithelium can cause a di¡usion barrier and subsequent intract-
able hypoxia.We have no insight into possible cell-mediated pul-
monary injury, however, which might be an important factor.
The pulmonary injury does not respond to medical treatment,
and the development of shortness of breath and hypoxia in a
patient with this syndrome is an ominous prognostic sign.
CONCLUSION
Although our knowledge of PNP has progressed substantially in
the last decade, much is still unknown.The disease occurs rapidly,
has a short and stormy progression in many patients, and leaves
us with a limited window of opportunity in which to study it in
individual cases.We hope that with increased recognition of PNP
more details of the mechanisms of autoimmune injury will be
de¢ned, allowing us to better treat these a¡ected patients.
This work has been supported in part by grant # RO1-AI 48063 from the National
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